Physician

Amy C Vander Woude, M.D.

According to 2025 Medicare claims, Amy Woude, M.D. (NPI: 1427059781) practices hematology/oncology in the Grand Rapids-Wyoming-Kentwood, MI market, with the plurality of this provider's patient population coming from Kent, MI. This provider's primary affiliated billing organization is CANCER & HEMATOLOGY CENTERS OF WESTERN MI, P.C. (NPI: 1528018389; TIN: 382777354) and primary practice location at 49503-2563. Woude is affiliated with the West Michigan Accountable Care Organization, LLC (ACO ID: A4626), participating under the MSSP model.

Woude's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 368 traditional Medicare patients, billed 79,486 HCPCS/CPT codes, and received $1,502,743 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,085 prescription claims across 489 beneficiaries totaling $4,459,062 in drug costs, led by Ibrance (Palbociclib). DME data shows 140 claims. Open Payments data shows 28 records totaling $380,852. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $1,660,442 and ending at $4,459,062. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	561	52,081	$1,300,459
2016	507	69,917	$1,317,135
2017	438	66,565	$1,266,339
2018	381	36,582	$809,933
2019	481	32,191	$876,949
2020	484	33,345	$886,156
2021	435	40,852	$773,895
2022	368	38,660	$901,109
2023	435	64,083	$1,426,279
2024	368	79,486	$1,502,743

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	440	2,204	$1,660,442
2016	447	2,107	$2,694,059
2017	411	1,842	$1,643,538
2018	398	1,710	$1,678,488
2019	445	1,664	$1,634,055
2020	484	1,736	$2,018,797
2021	507	1,697	$1,530,019
2022	486	1,682	$2,310,737
2023	477	1,819	$3,300,461
2024	489	2,085	$4,459,062

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	37	$8,771
2018	N/R	117	$16,094
2019	N/R	51	$5,792
2020	N/R	55	$5,181
2021	N/R	64	$5,639
2022	N/R	26	$1,034
2023	N/R	100	$18,744
2024	N/R	140	$4,063

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	155	280	$87
82306	Vitamin d-3 level	76	81	$29
80053	Blood test, comprehensive group of blood chemicals	77	406	$10
36415	Insertion of needle into vein for collection of blood sample	153	596	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	78	464	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ibrance	Palbociclib	172	4,836	$2,621,395
Orserdu	Elacestrant Hcl	26	741	$548,138
Kisqali	Ribociclib Succinate	35	980	$540,137
Verzenio	Abemaciclib	22	616	$333,914
Neulasta	Pegfilgrastim	21	434	$132,888

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	37	$1,491
L8000	Breast prosthesis, mastectomy bra, without integrated breast prosthesis form, any size, any type	N	N/R	13	$1,213
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	36	$602
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	26	$489
J8520	Capecitabine, oral, 150 mg	N	N/R	28	$268

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	14	$317	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	14	$380,535	AstraZeneca Pharmaceuticals LP
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Amy C. Vander Woude, M.D.?

Tedicare shows public-source Medicare data for Amy C. Vander Woude, M.D. (NPI 1427059781), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Amy C. Vander Woude, M.D. have ACO affiliation data?

Amy C. Vander Woude, M.D. is shown with ACO affiliation data for West Michigan Accountable Care Organization, LLC (MSSP, ACO ID A4626).

What billing organization is linked to Amy C. Vander Woude, M.D.?

Amy C. Vander Woude, M.D. is linked to CANCER & HEMATOLOGY CENTERS OF WESTERN MI, P.C. (billing NPI 1528018389) in the available physician profile data.

Does Amy C. Vander Woude, M.D. have Open Payments data?

Amy C. Vander Woude, M.D. has 28 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.